載入...
Belatacept Resistant Rejection is Associated with CD28(+) Memory CD8 T cells
Recently newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent is associated with superior patient survival and graft function than traditional therapy but its adoption as a m...
Na minha lista:
| 發表在: | Am J Transplant |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573634/ https://ncbi.nlm.nih.gov/pubmed/28502128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14349 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|